--- title: Pharma & Biotech Case Studies | 2040 Consulting description: Ensure compliance in Dubai & MENA. 2040 Consulting offers expert GxP, QMS, audit prep, and regulatory readiness, from batch release to recalls. --- # Explore Our Case Studies ## Proven GMP Results Delivered Under Pressure, On Time, and Globally Compliant Impact in different regions: [Case 1: Europe](https://www.2040consulting.com/casestudies#case1120M) [Case 2: NAM](https://www.2040consulting.com/casestudies#case2250M) [Case 3: EU](https://www.2040consulting.com/casestudies#case3QCLAB) [Case 4: US, PR,EU](https://www.2040consulting.com/casestudies#case4GlobalQC) [Case 5: EU](https://www.2040consulting.com/casestudies#case5ComplianceCrisis) [Case 6: India](https://www.2040consulting.com/casestudies#case6FDA483) # Explore Our Case Studies ## Proven GMP Results Delivered Under Pressure, On Time, and Globally Compliant Impact in different regions: [Case 1: Europe](https://www.2040consulting.com/casestudies#case1120M) [Case 2: NAM](https://www.2040consulting.com/casestudies#case2250M) [Case 3: EU](https://www.2040consulting.com/casestudies#case3QCLAB) [Case 4: US, PR,EU](https://www.2040consulting.com/casestudies#case4GlobalQC) [Case 5: EU](https://www.2040consulting.com/casestudies#case5ComplianceCrisis) [Case 6: India](https://www.2040consulting.com/casestudies#case6FDA483) --- #### **What We Do is Clear. Here’s What That Looks Like in the Real World.** From facility expansions and lab relocations to regulatory recovery and FDA close-outs, 2040 Consulting delivers GMP-critical results under tight timelines and global scrutiny. ![Vector 1](https://19898180.fs1.hubspotusercontent-na1.net/hubfs/19898180/Hubspot%20Marketplace/Knowledge%20base/Vector%201.svg) --- ---   #### **€120M Sterile BDS Expansion → Impact: Europe ** **- Project Type:** Full facility acceleration | EMA / HPRA / FDA **- Duration:** 18 months A new market contract required GMP-ready bulk-drug-substance manufacturing within 18 months. Missing the timeline would forfeit first-mover advantage and multi-year revenue. **- Results:** - Delivered €120M facility on schedule and inspection-ready - All CQV protocols executed with zero critical observations - First GMP batches released on time for market launch **- Our Role:** Embedded as senior project lead, we aligned engineering, CQV, and procurement, compressed the CQV timeline, and ensured zero regulatory slippage. Download the Full Case Study 1 ![circle-strategic](https://www.2040consulting.com/hs-fs/hubfs/circle-strategic.png?width=400&height=400&name=circle-strategic.png "circle-strategic")   #### **$250M Combination-Product Line Expansion → Impact: North America ** **- Project Type:** Device + packaging + serialization build | FDA / Health Canada **- Duration:** 18 months To capitalize on a new auto-injector opportunity, the client had to add a full device-packaging line on a sterile fill-finish campus—without halting live production. **- Results:** - Commercial lots released to US and Canada - FDA & Health Canada inspections passed with zero observations - First GMP batches released on time for market launch **- Our Role:** Acted as **GMP integration lead** across capital, validation, and QA, delivering an 18-month expansion with **zero production downtime**e. Download the Full Case Study 2 ![quality](https://www.2040consulting.com/hs-fs/hubfs/quality.png?width=400&height=400&name=quality.png "quality")   #### **QC Lab Relocation & Requalification → Impact: EU ** **- Project Type:** Lab move | HPRA / FDA **- Duration:** 12 months A solid-oral-dose site needed to move all QC functions—including stability and water testing—to a new building, without interrupting production or batch release. **- Results:** - All equipment calibrated and qualified on schedule - No observations during HPRA or FDA inspections - Stability program resumed with zero data integrity concerns **- Our Role:** Led the relocation end-to-end: capital approval, vendor coordination, change-controls, and full IOQ/PQ—all **without a single hour of production downtime**. Download the Full Case Study 3 ![regulatory](https://www.2040consulting.com/hs-fs/hubfs/regulatory.png?width=400&height=400&name=regulatory.png "regulatory")   #### **Global QC Method-Transfer → Impact: US, PR, EU ** **- Project Type:** Method transfer for 13 biologics | HPRA / FDA **- Duration:** 12 months To hit regulatory filing deadlines, 13 biologic products (20 methods each) had to be transferred from US and PR sites to 4 EU labs—amid resource constraints and stalled logistics. **- Results:** - 13 products / 20 methods each transferred to 4 labs - Zero repeat investigations - Awarded Corporate Project-Delivery Award for quality and timeline **- Our Role:** Acted as Method-Transfer Site Lead, aligning global teams, unblocking reagent supply, and executing the company’s **fastest transfer ever**. Download the Full Case Study 4 ![circle-strategic](https://www.2040consulting.com/hs-fs/hubfs/circle-strategic.png?width=400&height=400&name=circle-strategic.png "circle-strategic")   #### **Compliance Crisis Turnaround → Impact: EU ** **- Project Type:** Critical findings recovery | HPRA **- Duration:** 12 weeks HPRA issued multiple **Critical and Major** findings. Batch release froze, CAPAs ballooned, and reputation eroded by the week. **- Results:** - 100% deviation backlog cleared in 90 days - Full QMS rebuilt on schedule - No repeat findings on reinspection **- Our Role:** Led a single, senior-led taskforce to triage CAPAs, rebuild the QMS, and satisfy regulators before escalating penalties took hold. Download the Full Case Study 5 ![oper](https://www.2040consulting.com/hs-fs/hubfs/oper.png?width=400&height=400&name=oper.png "oper")   #### **FDA 483 / OAI Recovery → Impact: India ** **- Project Type:** OAI remediation | FDA **- Duration:** 24 months After receiving an FDA 483 with OAI status, the site faced halted batch release, regulatory heat, and investor pressure. Internal teams could not close fast enough. **- Results:** - US batch release reinstated while still under OAI - 60% deviation backlog cut in 90 days - Site moved toward compliance; remediation plan accepted by FDA **- Our Role:** Embedded a senior taskforce to lead risk-ranked CAPA closure, rebuild SOPs, restart manufacturing, and steer the site toward final FDA close-out. Download the Full Case Study 6 ![oper](https://www.2040consulting.com/hs-fs/hubfs/oper.png?width=400&height=400&name=oper.png "oper")       ##### Ready to Build a Track Record Like This? Let’s discuss how we can deliver for your site, your investors, or your regulators—with the same precision and speed. [Request a Call](https://www.2040consulting.com/meetings/pj-murphy) Request a Relevant Case Summary